Method for synthesis of benzamide derivatives or their pharmacologically acceptable salts

专利摘要:
Compounds of the general formula: wherein R¹ represents hydrogen, a C₁₋₆ alkyl group or an acetyl group;R² represents halogen;R³ represents a group of the formula: wherein R⁵ represents hydrogen or a phenyl or non-aromatic cyclic ether group and n is 2 or 3;R⁴ represents a C₃₋₆ cycloalkyl, cyclohexenyl, C₁₋₆ alkoxy, trifluoromethyl, tetrahydrofuryl, 1,3-dioxolanyl or phenoxy group;m is 0, 1, 2, 3 or 4 with the proviso that when m is 0, R⁴ is only a C₃₋₆ cycloalkyl or tetrahydrofuryl group;and pharmacologically acceptable acid addition salts, quaternary ammonium salts and N-oxides thereof have pharmacological properties rendering them useful as antiematic agents with reduced undesirable side-effects. Various methods are described for their preparation involving formation of the amide link, etherification of the 2-hydroxy derivative, introducing the R⁵CH₂ group on the N-unsubstituted azabicyclooctane or nonane or, for 4-amino compounds, by hydrolysing a 4-acylamino derivative.
公开号:SU1739849A3
申请号:SU884356273
申请日:1988-08-02
公开日:1992-06-07
发明作者:Вега Новерола Армандо；Мануэль Прието Сото Хосе；Пухоль Ногера Фернандо；Морагес Маури Хасинто；Жоффрей Вильям Спикетт Робер
申请人:Вальтон С.А.(Фирма)；
IPC主号:

专利说明:

The invention relates to the chemistry of derivatives of aromatic acids, specifically to the method of producing new benzamide derivatives of the general formula
C1
RjUHnfebCONHL
M0 (CH2) mR2
where, 1 or 2,
at
L1Јand
N

cm
R, is hydrogen, methyl or acetyl;
R2 With 5 C6 cycloalkyl, cyclohexenyl, methoxy, trifluoromethyl, tetrahydrofuryl, 1,3-dioxolanyl or phenoxy, and at. R
1- (sn2) p / h: n2-Kz
17398 9.k
where RA, R and m are as described above, are reacted with an amine of the general formula
5 LNH &,
R - HYDROGEN;
R is CyCg-cycloalkyl or methoxy group;
R is hydrogen, phenyl, 1,3 dioxol-anil or tetrahydrofuryl;
n 2 or 3,
or their pharmacologically acceptable salts, which have the ability to resist the central or peripheral action of dopamine, and can also contribute to the release of acetylcholine to muscarinic receptors of the smooth muscles of the gastrointestinal tract, and can be used as antiemetics and for the treatment of a wide range of gastrointestinal diseases of somatic, psychosomatic and atrogenic origin.
A number of new benzamides are known, among which H- (1-azabicycloЈ2,2, J-oct-3-yl) -2-methoxy-amino-5-chlorobenzamide (1 NN Zakoprid) as a strong antiemetic agent.
In contrast to other known anti-emetic compounds of the type of metaclopramide (N-2- (diethylaminoethyl) 2-methoxy-A amino-5-chlorobenzamide), the known compounds do not have an anti-depaminamine effect associated with extrapyramidal symptoms and side effects related to hyperprolactinemia. However, these benzamides give a more limited spectrum of antiemetic activity than metaclopramide, in particular, they are inactive in tests such as caused by CuSO, j. vomiting in dogs.
The aim of the invention is to create, on the basis of known methods, a method of producing new benzam Y derivatives, which show not only a wide range of antiemetic activity, but also showing the absence of side anti-dopaminergic effects.
The goal is achieved by the fact that benzoic acid of the general formula # 4
RtNH- Cb-COOH
OSSN2)
LNH &,
where L is indicated above
with the selection of the target product in free form or in the form of pharmacologically acceptable salts.
Example 1. To a solution of 2-cyclopropylmethoxy-amino-5 chlorobenzoic acid (3.2 g, 0.013 mol) in pyridine (15 ml) was added a solution of 3-aminoquinuclidine dihydrochloride (2.5 g, 0.0125 mol) and sodium hydroxide (0.5 g, 0.0125 mol) in water (15 ml). M, n-dicyclohexylcarbodiimide (3.1 g, 0, OH6 mol) is added to the resulting solution and the mixture is stirred for 20 hours at room temperature. An additional amount of carbodiimide (3.1 g, 0, mol) is added and stirring is continued for another 2A h. The insoluble material is filtered off, washed with water and the solvent is removed in vacuo at. The solid residue is taken up in water, alkalized with hydroxide.
sodium, the precipitated precipitate is filtered off and after drying, AND- (1-azabicyclo 2.2.2 oct-3-yl) -2-cyclopropylmethoxy-A-aminb-5-chlorobenzamide (I, 1 g) is obtained, mp. 183-185 ° С (after recrystallization from acetonitrile).
Example2. To a stirred solution of 2-methoxyethoxy-amino-5-chlorobenzoic acid (2.8 g,
0.0113 mol) in methylene chloride (125 ml) at (-5) - (- S) ° C, triethylamine (1.6 ml., 0.113 mol) and ethyl chloroformate (1.15 ml. 0.0113 mol) are added successively. After mixing
at the same temperature, a solution of 3 amino-8-methyl-8-aza-bicyclo 3,2, fj-octane (1.6 g, 0.01113 mol) in methylene chloride (-10 ml) is added at 2 hours. The temperature was maintained for 1 h (5) - (- S) ° C, after which it was left for a day at room temperature. The reaction mixture is washed with water, an aqueous solution of sodium hydroxide and again with water. After drying
(Na2-1 0) the solvent is removed in vacuo to give an oil that is reacted with a stoichiometric amount of fumaric acid. The boiling solution is diluted with isoprop
N- (8-methyl-8-azabicyclo-3, 2.1 oct-3-yl) -2- (2-methoxyethoxy) -4-amino-6-chlorobenzamide, fumarate crystallizes with nolom and cooling. 211-213 ° C (decomp.).
PRI me R 3. A mixture of H- (8-azabicyclo 3, 2, lJoKT-3-yl) cyclopropyl oxy-4-amino-5 chlorobenzamide (2.3 g, 0.007 mol), 2-bromomethyl -1,3-dioxalan (1.3 g, 0.0077 mol), potassium carbonate (1 g, 0.007 mol) and acetonitrile (100 ml) were boiled for 48 h, after which an additional 2 was added. β-bromomethyl-1,3-dioxolane (0.5 g, 0.003 mol). Reactionary. the mixture is boiled for another 48 hours, the solvent is removed in vacuo, the residue is taken up in water and extracted with methylene chloride. The organic solution, dried (), is decolorized with activated carbon and, after removing the solvent in vacuo, crude N-f8-2- (1,3-dioxalanyl) methyl 8-azabicyclorum 2.13-oct-3 yl | -2-cyclopropyl methoxy is obtained -4-amino 5-chlorobenzamide (2.2 g), which is purified by column chromatography on silica gel using a mixture of methanol and ammonium hydroxide (100: 1.5) as solvent, mp. 125-127 ° C.
An example. Suspension of N- (1-azabicyclo., 2.2 oct-3-yl) -2-hydroxy-4-acetamido-5-chlorobenzamide (6.75 g, 0.02 mol)) mp. x lorohydrate 315 317 ° C (decomp.), potassium carbonate (2.76 g, 0.02 mol), 91.5% bromomethyl cyclopropane (3.54 g, 0.024 mol) and methyl isobutyl ketone (40 ml) boil for 48 h After cooling, the reaction mixture is washed with water, 1N. an aqueous solution of sodium hydroxide and again with water. The organic solution is dried (provide activated carbon and, after removing the solvent in vacuo, crude NO-aza-bicyclo | 2.2.2 oct-3-yl) -2-cyclopropylmethoxy-4-acetamido-5-chlorobenzamide (6, 6 g) in the form of oil, which is crystallized from acetonitrile, so pl. 211-213 ° C (decomp.).
PRI me R 5o Solution M (1-aza-bicyclo 2.2.2 | oct-3-yl) -2-cyclopropylmethoxy-4-acetamido-5 chlorobenzam yes (3.9 g, 0.01 mol), sodium hydroxide (2 g, 0.05 mol), ethanol (50 ml) and water (20 ml) are boiled for 2 hours. Then ethanol is removed in vacuo, the residue is diluted with water, insoluble
ten
15
20
25 and

7398496
the substance is filtered off and washed thoroughly with water. The resulting N-O-aza bicyclo 2.2.2 oct-3-yl) -2-cyclopropylmethoxy-4-amino-5 chlorobenamic acid (3.2 g) is purified by recrystallization from acetonitrile, so pl. 183-185 ° C.
Example To a solution of N- (1-azabicyclo 2,2.2 oct-3-yl) -2-cyclopropylmethoxy-4-amino-5 chlorobenzamide (3.5 g, 0.01 mol) in acetone (200 ml ) iodomethane (2.8 g, 0.02 mol) is added, the mixture is stirred at room temperature for 20 h. The precipitate is collected, washed with acetone and after drying, N- (1-aabicicylor, 2.2 octa) -2 is obtained -cyclopropylmethoxy 4-amino-5-chlorobenzamide in the form of methyl iodides (3.9 g), so pl. 274-276 ° C (decomposition), after recrystallization from a mixture of acetonitrile and water.
Example. To a solution of N- (1 ablation Clo Ј 2,2,2 Doct-3-yl) -2-cyclopropylmethoxy-4-acetamido 5 chlorobenzamide (2.6 g, 0.007 mol) in acetic acid (20 ml) was added 30 % hydrogen peroxide (1.8 mol) and the resulting solution is stirred for 15 h at 80 ° C. The solvent is removed in vacuo, the residue is treated with water, basified with aqueous sodium hydroxide solution, saturated with sodium chloride and extracted with methylene chloride. The organic solution is dried (), the solvent is removed in vacuo, the resulting yellow substance is treated with diethyl ether and collected. After washing with diethyl ether and acetonitrile, 1.4 g (after drying at 50 ° C) of H (1-azabicycloG2.2.2 oct-3-yl) -2-cyclopropylmethoxy-4-acetamido-5 chlorobenzamide N are obtained. in the form of white matter, so pl. 234-236 C (decomp.).
Proposed compounds are listed in Table. 1-3.
Example 50,000 tablets each containing 1 mg of H- (1-azabicyclo-Ј2,2,2 oct-3-yl) -2-cyclopropylmethoxy-4-amino-5-chlorobenzamide are obtained from the following composition, g:
K- (1-Azabicyclo 2.2.27
Oct-3 yl) -2-cyclopropylmethoxy-4-amino-5
chlorobenzamide 50
Microcrystalline
cellulose950
thirty
35
40
45
SS
Splash-dried lactose 950 Carboxymethyl starch 200 Sodium fumaryl stearate 50 Colloidal silica 50 All powdered components are passed through a sieve with openings of 0.6 mm, then mixed in a suitable mixer for 20 minutes and pressed into tablets of 125 mg using round and flat bent punch 6 mm. The time of the destruction of the tablets is about 60 seconds.
Example 9: 2000 bottles, each containing a solution of L 25 mg of N- (1-azabicyclo 2,2.2 oct-3-yl) -2-cyclopropylmethoxy-amino-5 chlorobenzamide, are prepared as follows .
Composition, g:
N- (1 -Azabicyclo 2,2, oct-3 yl) -2-cyclopropylmethoxy-amino-5-chlorobenzamide 50
Sorbitol 120000
Sorbic acid 250 Citric acid 250 Distilled water g.s.250 l Odorant g.So
N- (1-Azabicyclo 2,2.2 oct-3-yl) -2-cyclopropylmethoxy-amino-5-chlorobenzamide and sorbic acid are dissolved in 150 l of water and then, with stirring, sorbitol, citric acid is added to dissolve acid and perfume. The mixture is diluted to 250 liters and bottled in 125 ml bottles using an appropriate filling machine.
An example. 10,000 ampoules, each containing 0.5 mg of N- (1-azabicyclo 2,2.2 oct-3 yl) -2-cyclopropylmethoxy-4-amino-5 chlorobenzamide, are obtained on the basis of the following composition:
N- (1-Azabicyclo 2,2, oct-3-yl) 2-cyclopropylmethoxy-amino-5 chlorobenzamide 5
Sodium chloride 250 Lactic acid 7 1 n. sodium hydroxy solution g.s. Up to pH 3 g.s. 50 l
ten
15
20
25
The benzamide, lactic acid, and sodium chloride are dissolved in 0 L of water. The resulting solution is neutralized to pH 3 j with sodium hydroxide solution, diluted to 50 liters, then passed through a bacteria-retaining filter, and glass ampoules of 5 ml are filled in a known manner under sterile conditions.
PRI me R 11. 5000 candles, each of which contains 1 mg of N- (1-eza-bicyclo 2,2,2 oct-3-yl) -2-cyclopropylmethoxy-amino-5-chlorobenzamide, obtained as follows, g:. N- (1-Azabicyclo 2,2.2 oct-3-yl) -2-cyclopropylmethoxy-amino-5-chlorobenzamide 5
Theobromic oil 9995
Theobromic oil is melted and the active compound is suspended in it. The mixture is then filled in the appropriate candle molds to make 2 g candles.
Example 12: 100,000 capsules, each containing 1 mg of N- (1-azabicyclo 2.2.2 oct-3 yl) -2-cyclopropylmethoxy-amino-5-chlorobenzamide-30, are obtained in the following way.
Composition, g:
N- (1 -Azabicyclo 2,2.2 oct-3-yl) -2-cyclopropylmethoxy-amino-5-chlorobenzamide
Lactose
Corn starch
Colloidal oxide
flint
Magnesium stearate
All powder components are preliminarily passed through a 0.6 mm sieve, then mixed for 20 minutes, then the resulting mixture is filled into ampoules of the desired size (100,000 pieces) using a dosing machine.
The N-substituted benzamides of the proposed formula exhibit strong gastro-kinetic and anti-emetic activity and block 5-TTj receptors without antagonistic effect to dopamine and have low toxicity.
Pharmacological selection of compounds in order to optimize these effects is carried out using the following tests: stimulation of pu35
40
100
10,500
9000
200 200
45
50
55
H- (1-Azabicyclo 2,2,2-oct-3-yl) - to those 5-GT from 5-GT-receptors, to 2-cyclopropylmethoxy-amino-5-chloro-halogen in vagal efferent tissue g oernz- about
ten
15
20
25
7398498
The benzamide, lactic acid, and sodium chloride are dissolved in 0 L of water. The resulting solution is neutralized to pH 3 j with sodium hydroxide solution, diluted to 50 liters, then passed through a bacteria-retaining filter, and glass ampoules of 5 ml are filled in a known manner under sterile conditions.
PRI me R 11. 5000 candles, each of which contains 1 mg of N- (1-eza-bicyclo 2,2,2 oct-3-yl) -2-cyclopropylmethoxy-amino-5-chlorobenzamide, obtained as follows, g:. N- (1-Azabicyclo 2,2.2 oct-3-yl) -2-cyclopropylmethoxy-amino-5-chlorobenzamide 5
Theobromic oil 9995
Theobromic oil is melted and the active compound is suspended in it. The mixture is then filled in the appropriate candle molds to make 2 g candles.
Example 12: 100,000 capsules, each containing 1 mg of N- (1-azabicyclo 2.2.2 oct-3 yl) -2-cyclopropylmethoxy-amino-5-chlorobenzamide-30, are obtained in the following way.
Composition, g:
N- (1 -Azabicyclo 2,2.2 oct-3-yl) -2-cyclopropylmethoxy-amino-5-chlorobenzamide
Lactose
Corn starch
Colloidal oxide
flint
Magnesium stearate
All powder components are preliminarily passed through a 0.6 mm sieve, then mixed for 20 minutes, then the resulting mixture is filled into ampoules of the desired size (100,000 pieces) using a dosing machine.
The N-substituted benzamides of the proposed formula exhibit strong gastro-kinetic and anti-emetic activity and block 5-TTj receptors without antagonistic effect to dopamine and have low toxicity.
Pharmacological selection of compounds in order to optimize these effects is carried out using the following tests: stimulation of pu35
40
100
10,500
9000
200 200
45
50
55
- those 5-GT from 5-GT receptors located in the vagal efferent tissue
91
nx- leads to a decrease in heart rate and blood pressure in anesthetized rats (Bezold – Jarish reflex); cis-platinum induced vomiting in dogs with the administration of the compounds by the oral or intravenous route; CuSCty-induced vomiting in dogs with subcutaneous or intravenous administration of the compounds; apomorphine induced vomiting in dogs with administration of the compounds subcutaneously or intravenously; emptying of the stomach with oral administration of the compounds.
The N-Substituted benzamides of the proposed formula are compared with metoclopramide (N- Јz- (diethylamino) methoxy-A-amino-5-chlorobenzamide) and Zakopridom (L- (1-azabicyclo 2.2, oct-3 yl) -2- methoxy-α-amino-5-chlorobenzamide), as a result of which it is shown that these compounds possess anti-emetic properties for the budgeting of new substituents in the 2-position of the benzamide group.
As can be seen from the table. 3, compounds of the general formula strongly inhibit the Bezold – Yarish reflex in rats at dosages 100-800 times lower compared to metoclopramide. Such activity is attributed to the ability to counteract drug-induced cytotoxic vomiting. All compounds inhibit cisplatin-induced vomiting in dogs, in particular the proposed compound shows the same activity as Zacoprid.
Metoclopramide reduces the number of cases caused by vomiting in dogs,
The novel compounds exhibit significant activity in the same test, while Zacopride is completely inactive.
Like Zacoprid, new compounds do not exhibit antiemetic activity in the test with apomorphine-induced vomiting in dogs, while metoclopramide is a very active compound in the same test. All compounds show good prokinetic activity in rat testing with emptying of the stomach from glass beads.
Thus, the N-substituted benzamides of the proposed formula have a wider spectrum of antiemetic activity compared to Zakoprd without antagonistic activity.





0
five
0
ten
to dopamine metoclopramide and, as a result, without the potential for concomitant extrapyramidal side effects.
N-Substituted benzamides of the general formula, due to their anti-5 GT activity, also exhibit anesthetic, tranquilizing, and anti-migraine activity.
Pharmaceutical compositions may contain as active ingredient at least one compound of the proposed formula or a pharmaceutically acceptable salt thereof in admixture with a pharmaceutically acceptable carrier or diluent. The active ingredient is used in an amount of 0.0001-99% by weight, preferably 0.001-90% by weight of the composition, depending on the nature of the composition, and further dilution will be required before use. The compositions are recommended to be formulated for oral, general, dermal or parenteral administration.
Pharmaceutically acceptable carriers or diluents miscible with the active compound or compounds or salts of these compounds to form the proposed compositions are well known, and the choice of a particular excipient depends on the proposed method of administering the compositions. The compositions recommend to prepare for
5 introduction per. In this case, compositions for oral administration can be in the form of tablets, capsules, wafers or effervescent granules, or liquid compositions, such as mixtures, elixirs, syrups or suspensions, each of which contains one or more compounds of the invention. Such drugs can be obtained by known methods.
Diluents that can be used in the manufacture of compositions include liquid and solid diluents that are compatible with the active ingredient, in a mixture with dyes or perfumes. Tablets or capsules usually contain 0.1-20 mg of the active ingredient or an equivalent amount of salt with an acid.
0
0
five
0
Liquid compositions intended for oral administration may be in the form of solutions or suspensions. It may be an aqueous solution of a soluble salt or other derivative.
 1117
in a mixture, for example with sucrose, to form a syrup. Suspensions may include an insoluble active compound or its pharmaceutically acceptable salt in a mixture with water, a suspending agent or a perfume.
Compositions for parenteral administration can be prepared from soluble salts, which can be dried or not freeze-dried, and which can be dissolved in water or a liquid that is acceptable for parenteral injection.
A method of treating various gastrointestinal disorders, including vomiting in mammals, including humans, is carried out by administering an effective amount of a compound or salt of the inventive formula using the compositions described and by administering. Effective doses typically range in the range of 0.1-100 mg of active compound per day.
The compounds of the general formula may be admixed with active anti-acid or anti-ulcer agents (with the exception of anti-cholinergic agents) for oral or, in appropriate cases, parenteral use.

权利要求:
Claims (1)
[1]
Thus, the proposed method allows to obtain benzamide derivatives having valuable pharmacological properties. Invention Formula
The method of obtaining the amide derivatives of the general formula
C1
RtNH- U-CONHL No. Н2) hC
where, 1 or 2, with
12
L
N
- hydrogen, methyl or acetyl; CCB cycloalkyl, cyclohexenyl, methoxy, trifluoromethyl, tetrahydrofuryl, 1,3 dioxolanyl or phenoxy group, and with L № Н,) П
R
N-CH2
3
hydrogen;
C3-Sb-cycloalkyl or meth-hydroxy;
Cs is hydrogen, phenyl, 1,3-dioxolanyl or tetrahydrofurfuryl;
 or 3,
or their pharmacologically acceptable salts, characterized in that the benzoic acid of the general formula
C1
RlNH- U-COOH
0 (CH2) mR2
where R ,, R and m have the indicated meanings,
subjected to interaction with the amine of the General formula
LNH2,
where L has the specified value, with the selection of the target product in free form or in the form of pharmacologically acceptable salts.
13
1739849
Cl
14 Table 1
RtHN- -CONH- j 0 (CH2) ffiR2 N.
15
1739HF9
 Fumaric acid.
Note. Compound 11: And- (1-eabicyclo 2,2.2 oct-3-ip-2-methoxyethoxy-α-amino-5-chlorobenzamide; compound 1: I- (1-asa-6cyclo 2 2.2 oct -} - un) -2-cyclopropylmethoxy- (α-amino-5-chloro-n-amide; compound 23: n- (8-iethyl-B-azabicyclo 3.2, oooct-3p-ip) -2-m-oxyethoxy-α-amino-5-chlorobenzane; compound 16: H (8-metip-8-azabicilor, 2.1 oct-3p-i) -2, -cyclopropylmethoxy- (-anino-5-chloro-ene-amide.
"
Continued table. 2
T-a blitz 3

类似技术:

---

公开号 | 公开日 | 专利标题

---

SU1739849A3|1992-06-07|Method for synthesis of benzamide derivatives or their pharmacologically acceptable salts

---

Clarke et al.1973|Compounds affecting the central nervous system. 4. 3. beta.-phenyltropane-2-carboxylic esters and analogs

---

FI91637B|1994-04-15|Process for the preparation of pharmacologically active quinuclidines

---

JP2502343B2|1996-05-29|A pharmaceutically active substituted benzamide

---

EP0297380B1|1994-10-05|Indolyl propanols, process for their preparation, their uses and preparation containing them

---

FI89168B|1993-05-14|PROCEDURE FOR THE PREPARATION OF PHARMACEUTICAL ACTIVE N-PIPERIDYLBENZAMIDER

---

EP0739892B1|2002-09-25|Chromone derivatives

---

KR860001252B1|1986-09-01|Process for preparing 9-|propyl) carbazole

---

US3850922A|1974-11-26|5-endo-benzoyloxy-n-|alkyl)bicyclo|heptane-2,3-diendo-carboxylic acid imides

---

EP0085899B1|1986-10-29|Pyridobenzodiazepinones, process for their preparation and pharmaceutical compositions containing them

---

DD300105A5|1992-05-21|New R | 3-quinuliclidinol derivatives

---

US5096900A|1992-03-17|methyl-2,3-dihydro-1h-isoindole and -2,3,4,5-tetrahydro-1h-benzazepine derivatives, their preparation and their application in therapy

---

DE69918046T2|2005-07-14|Novel basic derivatives of benz | isoindol-1-ones and pyrrolo | quinolin-1-ones with 5-HT3 antagonist activity, their production and their therapeutic use

---

JPH0681754B2|1994-10-19|Process for producing enantiomers having absolute configuration S or R of 3-aminoquinuclidine

---

DE2852945A1|1980-06-26|Benzo:dioxanyl-hydroxyethyl-piperidyl-imidazolidone derivs. - having hypotensive activity, and prepd. by reacting a piperidin-4-yl-imidazolidinone with a halo-hydroxyethyl-benzodioxan

---

EP0085893B1|1986-05-14|Pyridobenzodiazepinones, process for their preparation and pharmaceutical compositions containing them

---

DE1115259B|1961-10-19|Process for the production of iminodibenzylene

---

DE2705949C2|1983-04-21|4- | piperidine derivatives, a process for their preparation and pharmaceutical compositions containing them

---

EP0001585B1|1981-07-22|Piperazino-pyrrolobenzodiazepines, methods for their preparation and pharmaceutical compositions containing them

---

EP0506903A1|1992-10-07|4-acetoxy-piperidine derivatives, process for their preparation and use as a muscarinic m3-receptor antagonist

---

EP0086981B1|1986-09-10|Substituted thienobenzodiazepinones, process for their preparation and medicines containing these compounds

---

DE19526233B4|2006-09-07|Hydroxylated azabicyclooctyl-tetra- and -hexahydrobenz [d, e] isoquinolones, their preparation and pharmaceutical compositions containing them

---

DE3248094C1|1984-06-14|7H-Dibenzo | cyclohepten-5-one | derivatives, process for their preparation and their use in combating mental illnesses and gastric and / or intestinal ulcers

---

DE2508251A1|1976-09-09|4-| indoles - with beta-blocking activity for treating cardiovascular disorders

---

DE2458179C3|1977-12-01|Disubstituted azabicycloalkanes, their salts, processes for their production and pharmaceutical preparations

同族专利:

---

公开号 | 公开日

---

PH25048A|1991-01-28|

---

JPS6450883A|1989-02-27|

---

AU2029388A|1989-02-09|

---

EP0302699A2|1989-02-08|

---

US4937236A|1990-06-26|

---

PT88175A|1989-06-30|

---

NZ225657A|1991-07-26|

---

CS539788A2|1990-06-13|

---

HUT48246A|1989-05-29|

---

MX12478A|1993-12-01|

---

NO883428D0|1988-08-02|

---

CS272794B2|1991-02-12|

---

FI883592A|1989-02-04|

---

NO168422C|1992-02-19|

---

DD282010A5|1990-08-29|

---

DK429988D0|1988-08-02|

---

NO883428L|1989-02-06|

---

IL87080A|1992-09-06|

---

IL87080D0|1988-12-30|

---

HU200460B|1990-06-28|

---

EP0302699A3|1990-07-11|

---

NO168422B|1991-11-11|

---

ZA885418B|1989-04-26|

---

AU629175B2|1992-10-01|

---

DK429988A|1989-04-05|

---

US4877780A|1989-10-31|

---

GB8718345D0|1987-09-09|

---

FI883592A0|1988-08-01|

---

CN1031701A|1989-03-15|

---

PL154302B1|1991-07-31|

---

KR890003760A|1989-04-17|

---

PL274010A1|1989-10-16|

---

RO101203B|1992-01-10|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

---

EP0068700A1|1981-06-29|1983-01-05|Beecham Group Plc|Azobicycloalkylbenzamides, process for their preparation and pharmaceutical compositions containing them|

---

FR2529548B1|1982-07-02|1985-04-19|Delalande Sa|

---

EP0099194A3|1982-07-03|1984-04-11|Beecham Group Plc|Novel benzamides|

---

EP0102195A3|1982-08-03|1984-04-11|Beecham Group Plc|Substituted aza bicycloalkyl derivatives with dopamine antagonist activity|

---

US4820715A|1984-06-28|1989-04-11|Bristol-Myers Company|Anti-emetic quinuclidinyl benzamides|

---

US4808624A|1984-06-28|1989-02-28|Bristol-Myers Company|Pharmacologically active substituted benzamides|

---

US4870181A|1985-02-04|1989-09-26|A. H. Robins Company, Incorporated|Process for the preparation of 2-alkoxy-N-octan-3-yl)aminobenzamides|

---

EP0220011A3|1985-10-12|1990-01-03|Beecham Group Plc|Use of azabicloalkylbenzamides in the treatment of gastrointestinal motility disorders, migraine, emesis, cluster headaches, trigeminal neuralgia and arrhythmia|

---

US4717563A|1986-03-05|1988-01-05|A. H. Robins Company, Inc.|2-alkoxy-N-oct-3-yl) benzamides and thiobenzamides in a method for alleviating emesis caused by non-platinum anticancer drugs|US4820715A|1984-06-28|1989-04-11|Bristol-Myers Company|Anti-emetic quinuclidinyl benzamides|

---

EP0295350B1|1987-06-17|1992-11-11|Laboratoires DELAGRANGE|Use of N-[2-ethyl]-2-methoxy-4-[amino]-5-chlorobenzamide as an anxiolytic and antipsychotic agent|

---

FR2640139A1|1988-12-14|1990-06-15|Delagrange Laboratoires|APPLICATION OF BENZAMIDES SUBSTITUTED AS GASTROMOTORS|

---

FR2640507A1|1988-12-20|1990-06-22|Delagrange Laboratoires|APPLICATION OF BENZAMIDES SUBSTITUTED AS ANXIOLYTICS AND ANTI-PSYCHOTICS|

---

IL100432A|1990-12-27|1996-01-19|Erba Carlo Spa|Dihydrobenzofuran carboxamide derivatives their preparation and pharmaceutical compositions containing them|

---

US5395832A|1991-02-15|1995-03-07|Hokuriku Seiyaku Co., Ltd.|Benzamide derivatives|

---

TW243449B|1991-02-15|1995-03-21|Hokuriku Pharmaceutical|

---

DK0554794T3|1992-02-04|1999-04-26|Eisai Co Ltd|aminobenzoic|

---

US5236931A|1992-03-26|1993-08-17|A. H. Robins Company, Incorporated|2-substituted benzamide and benzoate derivatives of 3-aminoquinuclidine and 3-quinuclidinol|

---

US5864039A|1994-03-30|1999-01-26|Yoshitomi Pharmaceutical Industries, Ltd.|Benzoic acid compounds and use thereof as medicaments|

---

US5723103A|1994-12-09|1998-03-03|Vanderbilt University|Substituted benzamides and radioligand analogs and methods of use|

---

US6083991A|1997-06-04|2000-07-04|University Of Florida Research Foundation, Inc.|Anti-arrhythmic composition and methods of treatment|

---

AR022338A1|1999-02-04|2002-09-04|Hokuriku Pharmaceutical|A BENZAMIDE COMPOUND, A MEDICINAL PRODUCT CONTAINING IT, AND USE FOR THE MANUFACTURE OF A MEDICINAL PRODUCT FOR THE TREATMENT OR PREVENTION OF A DIGESTIVE DISEASE OR TO IMPROVE THE MOBILITY OF THE GASTROINTESTINAL TRACT.|

---

ES2165768B1|1999-07-14|2003-04-01|Almirall Prodesfarma Sa|NEW DERIVATIVES OF QUINUCLIDINE AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM.|

---

US6479510B2|2000-08-18|2002-11-12|Pharmacia & Upjohn Company|Quinuclidine-substituted aryl compounds for treatment of disease|

---

AU8287301A|2000-08-18|2002-03-04|Upjohn Co|Quinuclidine-substituted aryl compounds for treatment of disease|

---

KR100381886B1|2001-03-21|2003-04-26|유니모씨엔티 주식회사|Cdma signal detection apparatus of relay station for wireless communication|

---

PE20021019A1|2001-04-19|2002-11-13|Upjohn Co|SUBSTITUTED AZABYCLE GROUPS|

---

WO2003018586A1|2001-08-24|2003-03-06|Pharmacia & Upjohn Company|Substituted-aryl 7-aza[2.2.1]bicycloheptanes for the treatment of disease|

---

US6852716B2|2002-02-15|2005-02-08|Pfizer Inc|Substituted-aryl compounds for treatment of disease|

---

AU2003214936A1|2002-02-20|2003-09-09|Pharmacia And Upjohn Company|Azabicyclic compounds with alfa7 nicotinic acetylcholine receptor activity|

---

EP2100599A1|2008-03-13|2009-09-16|Laboratorios Almirall, S.A.|Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease|

---

PL2432467T3|2009-05-20|2018-07-31|INSERM |Serotonin 5-ht3 receptor antagonists for use in the treatment of lesional vestibular disorders|

---

EP2253316B1|2009-05-20|2013-08-14|INSERM |Serotonin 5-HT3 receptor antagonists for use in the treatment or prevention of an inner ear pathology with vestibular deficits|

---

EP2510928A1|2011-04-15|2012-10-17|Almirall, S.A.|Aclidinium for use in improving the quality of sleep in respiratory patients|

---

US9692588B2|2015-07-07|2017-06-27|Samsung Electronics Co., Ltd.|System and method for performing synchronization and interference rejection in super regenerative receiver |

法律状态:

优先权:

---

申请号 | 申请日 | 专利标题

---

GB878718345A|GB8718345D0|1987-08-03|1987-08-03|N-substituted benzamides|

---